Gastrointestinal Stromal Tumors, Sarcoma
Conditions
Keywords
GIST, Imatinib, Adjuvant therapy, Kit mutation
Brief summary
The presence of c-kit mutation is an independent poor prognostic factor for relapse in addition to large size (\> 5 cm) and high mitotic rate (\> 5/50 high power field \[HPF\]) in localized gastrointestinal stromal tumor (GIST) patients who underwent complete surgical resection. In addition, the localized GIST which had exon 11 c-kit mutation and features of high-risk for relapse according to National Institute of Health (NIH) consensus guideline (tumor size \> 10 cm or mitotic count \> 10/50 HPF) also have high-risk of relapse. Until recently, there has been no effective therapy for advanced, unresectable GISTs. However, a new agent, imatinib mesylate, has shown promise in the metastatic setting, and c-kit exon 11 mutation is the strongest prognostic factor for better response and survival. It is reasonable to try imatinib in an earlier and minimal residual status especially for patients at higher risk of relapse and a higher probability of response to imatinib.
Interventions
Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
Sponsors
Asan Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven diagnosis of GIST, with positive immunostaining for KIT (CD117) * Tumor size \> 5 cm and mitotic rate \> 5/50HPF(High Power Field), or tumor size \> 10 cm irrespective of mitotic rate, or mitotic rate \> 10/50 HPF irrespective of tumor size. * Presence of mutation in exon 11 of c-kit gene. * Surgery performed from 3 weeks to 8 weeks before administration of Imatinib mesylate. * No evidence of residual macroscopic and microscopic disease after surgery. * Absence of distant metastases * No prior radiation therapy, no prior chemotherapy, no prior therapy with Imatinib mesylate, or any other molecular targeted or biological therapy. * Age 18 yrs or older * ECOG(Eastern Cooperative Oncology Group electrocorticogram) performance status = 0-2 * No New York Heart Association (NYHA) Class 3\ 4 cardiac problems * Absence of severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes, uncontrolled chronic renal disease, uncontrolled liver disease, including chronic viral hepatitis judged at risk of reactivation, uncontrolled active infection, such as human immunodeficiency virus (HIV) infection, etc.). * No ongoing pregnancy or nursing.. * No prior, or ongoing other malignancy, except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or adequately treated cancer with eradicative intent for which the patient has been continuously disease-free for 5 years. * No use of coumarin derivatives at the time of treatment start. * Adequate liver function, as defined by a serum bilirubin \< 1.5 x the institutional upper limit of normal (IULN), aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 2.5 IULN, obtained within 7 days prior to randomization. * Adequate renal function, as defined by a serum creatinine \< 1.5 x IULN, obtained within 7 days prior to randomization. * Absolute neutrophil count (ANC) \> 1.5 x 109/l and a platelet count \> 100 x 109/l obtained within 7 days prior to randomization. Baseline hemoglobin \> 9 g/dl (this may be achieved by transfusions if needed). * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year Relapse Free Survival Rate | 2 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 2-year Overall Survival Rate | 2 years | — |
| Toxicity Profile | Monitoring of adverse events will be continued for at least 28days following the last dose of study treatment, up to 3 years. | Number of patients who experienced toxicity from study treatment to evaluate the safety and tolerability of adjuvant imatinib |
Countries
South Korea
Participant flow
Recruitment details
Forty-eight patients were enrolled at four centers in South Korea between August 2005 and June 2007.
Pre-assignment details
One patient was excluded from the study before treatment initiation because of metastatic disease.
Participants by arm
| Arm | Count |
|---|---|
| Imatinib Mesylate patients receiving adjuvant imatinib mesylate | 47 |
| Total | 47 |
Baseline characteristics
| Characteristic | Imatinib Mesylate |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 12 Participants |
| Age, Categorical Between 18 and 65 years | 35 Participants |
| Age, Continuous | 56.3 years STANDARD_DEVIATION 10 |
| Region of Enrollment Korea, Republic of | 47 participants |
| Sex: Female, Male Female | 23 Participants |
| Sex: Female, Male Male | 24 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 47 / 47 |
| serious Total, serious adverse events | 0 / 47 |
Outcome results
Primary
2-year Relapse Free Survival Rate
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Imatinib Mesylate | 2-year Relapse Free Survival Rate | 93.6 percentage of participants |
Secondary
2-year Overall Survival Rate
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Imatinib Mesylate | 2-year Overall Survival Rate | 97.9 percentage of participants |
Secondary
Toxicity Profile
Number of patients who experienced toxicity from study treatment to evaluate the safety and tolerability of adjuvant imatinib
Time frame: Monitoring of adverse events will be continued for at least 28days following the last dose of study treatment, up to 3 years.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Imatinib Mesylate | Toxicity Profile | 47 participants |